The global market for Metabolomics is estimated at US$3.5 Billion in 2023 and is projected to reach US$9.0 Billion by 2030, growing at a CAGR of 14.4% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. ![Global Metabolomics Market]( "Global Metabolomics Market")
The expansion of metabolomics is driven by several key factors, including advancements in analytical and diagnostic technologies that allow for precise implant placements and the development of materials like zirconia as alternatives to traditional substances like titanium, offering new options for patients. The integration of digital dentistry through CAD/CAM technologies has streamlined implant design and fabrication processes, reducing turnaround times and enhancing customization. Increased consumer awareness and preferences for durable and aesthetically pleasing solutions such as implants, alongside the growing acceptance of cosmetic dentistry, have significantly contributed to the market demand. Improved insurance coverage and financing options have made these advanced treatments more accessible, broadening the patient base. Additionally, the global rise in the aging population who may require dental restorations further propels the demand for dental implants, ensuring ongoing market growth and innovation.
The expansion of metabolomics is driven by several key factors, including advancements in analytical and diagnostic technologies that allow for precise implant placements and the development of materials like zirconia as alternatives to traditional substances like titanium, offering new options for patients. The integration of digital dentistry through CAD/CAM technologies has streamlined implant design and fabrication processes, reducing turnaround times and enhancing customization. Increased consumer awareness and preferences for durable and aesthetically pleasing solutions such as implants, alongside the growing acceptance of cosmetic dentistry, have significantly contributed to the market demand. Improved insurance coverage and financing options have made these advanced treatments more accessible, broadening the patient base. Additionally, the global rise in the aging population who may require dental restorations further propels the demand for dental implants, ensuring ongoing market growth and innovation.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Biomarker Discovery Application segment, which is expected to reach US$3.6 Billion by 2030 with a CAGR of a 16.0%. The Drug Discovery Application segment is also set to grow at 14.2% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $965.8 Million in 2023, and China, forecasted to grow at an impressive 13.6% CAGR to reach $1.4 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Metabolomics Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Metabolomics Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Metabolomics Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as AB Sciex LLC, African Biosciences Ltd, Agilent Technologies, Inc., and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 31 Featured):
- AB Sciex LLC
- African Biosciences Ltd
- Agilent Technologies, Inc.
- Agios Pharmaceuticals, Inc.
- Berg LLC
- BioCat GmbH
- Biocenter Finland
- Biocrates Life Sciences AG
- Biogenetics
- Bio-Rad Laboratories, Inc.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISREST OF WORLDIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- Metabolomics - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
3. MARKET TRENDS & DRIVERS
- Rising Focus on Personalized Medicine Throws the Spotlight on Metabolomics
- Increasing Use of Metabolomics in Nutritional Research Generates Market Opportunities
- Technological Advancements in Analytical Techniques Propel Growth in Metabolomics
- Increasing Application of Metabolomics in Biomarker Discovery Expands Addressable Market Opportunity
- Growing Investments in R&D Strengthen Business Case for Metabolomics
- Integration with Systems Biology Generates Demand for Advanced Metabolomics Solutions
- Increasing Prevalence of Chronic Diseases Sustains Growth in Metabolomics Market
- Here’s How AI and Big Data Analytics Accelerate Demand for Metabolomics
- Expansion of Metabolomics in Nutrigenomics Propels Market Growth
- Growing Demand for Non-Invasive Diagnostic Techniques Drives Adoption of Metabolomics
- Rising Use of Metabolomics in Environmental and Agricultural Research Spurs Growth
- Here’s the Story: Evolution of Metabolomics and its Market Impact
- Advancements in Mass Spectrometry and NMR Technology Strengthen Business Case for Metabolomics
- Increasing Adoption of Metabolomics in Drug Discovery and Development Expands Market Potential
- Growing Awareness of Metabolomics in Clinical Applications Sustains Market Growth
- Here’s How Personalized Nutrition Trends Propel Growth in Metabolomics
- Growing Adoption of Omics Technologies in Life Sciences Drives Market Expansion
- Rising Interest in Metabolomics for Microbiome Studies Expands Addressable Market Opportunity
- Focus on Metabolomics in Toxicology Studies Strengthens Business Case for the Technology
- Growing Adoption of Metabolomics in Plant and Food Science Propels Market Growth
- Here’s How Innovations in Metabolomics Platforms Drive Market Adoption
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Metabolomics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
- Table 2: World Recent Past, Current & Future Analysis for Metabolomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
- Table 3: World Historic Review for Metabolomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 4: World 16-Year Perspective for Metabolomics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
- Table 5: World Recent Past, Current & Future Analysis for Biomarker Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
- Table 6: World Historic Review for Biomarker Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 7: World 16-Year Perspective for Biomarker Discovery by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- Table 8: World Recent Past, Current & Future Analysis for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
- Table 9: World Historic Review for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 10: World 16-Year Perspective for Drug Discovery by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- Table 11: World Recent Past, Current & Future Analysis for Toxicology Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
- Table 12: World Historic Review for Toxicology Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 13: World 16-Year Perspective for Toxicology Testing by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- Table 14: World Recent Past, Current & Future Analysis for Nutrigenomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
- Table 15: World Historic Review for Nutrigenomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 16: World 16-Year Perspective for Nutrigenomics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- Table 17: World Recent Past, Current & Future Analysis for Functional Genomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
- Table 18: World Historic Review for Functional Genomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 19: World 16-Year Perspective for Functional Genomics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- Table 20: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
- Table 21: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 22: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- Table 23: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
- Table 24: World Historic Review for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 25: World 16-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- Table 26: World Recent Past, Current & Future Analysis for Pharmaceutical & Biotechnology Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
- Table 27: World Historic Review for Pharmaceutical & Biotechnology Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 28: World 16-Year Perspective for Pharmaceutical & Biotechnology Companies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- Table 29: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
- Table 30: World Historic Review for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 31: World 16-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- Table 32: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
- Table 33: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 34: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
UNITED STATES
- Metabolomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
- Table 35: USA Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 36: USA Historic Review for Metabolomics by Application - Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 37: USA 16-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics and Other Applications for the Years 2014, 2024 & 2030
- Table 38: USA Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 39: USA Historic Review for Metabolomics by End-Use - Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 40: USA 16-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End-Uses for the Years 2014, 2024 & 2030
CANADA
- Table 41: Canada Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 42: Canada Historic Review for Metabolomics by Application - Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 43: Canada 16-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics and Other Applications for the Years 2014, 2024 & 2030
- Table 44: Canada Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 45: Canada Historic Review for Metabolomics by End-Use - Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 46: Canada 16-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End-Uses for the Years 2014, 2024 & 2030
JAPAN
- Metabolomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
- Table 47: Japan Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 48: Japan Historic Review for Metabolomics by Application - Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 49: Japan 16-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics and Other Applications for the Years 2014, 2024 & 2030
- Table 50: Japan Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 51: Japan Historic Review for Metabolomics by End-Use - Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 52: Japan 16-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End-Uses for the Years 2014, 2024 & 2030
CHINA
- Metabolomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
- Table 53: China Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 54: China Historic Review for Metabolomics by Application - Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 55: China 16-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics and Other Applications for the Years 2014, 2024 & 2030
- Table 56: China Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 57: China Historic Review for Metabolomics by End-Use - Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 58: China 16-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End-Uses for the Years 2014, 2024 & 2030
EUROPE
- Metabolomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
- Table 59: Europe Recent Past, Current & Future Analysis for Metabolomics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
- Table 60: Europe Historic Review for Metabolomics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 61: Europe 16-Year Perspective for Metabolomics by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
- Table 62: Europe Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 63: Europe Historic Review for Metabolomics by Application - Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 64: Europe 16-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics and Other Applications for the Years 2014, 2024 & 2030
- Table 65: Europe Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 66: Europe Historic Review for Metabolomics by End-Use - Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 67: Europe 16-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End-Uses for the Years 2014, 2024 & 2030
FRANCE
- Metabolomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
- Table 68: France Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 69: France Historic Review for Metabolomics by Application - Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 70: France 16-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics and Other Applications for the Years 2014, 2024 & 2030
- Table 71: France Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 72: France Historic Review for Metabolomics by End-Use - Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 73: France 16-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End-Uses for the Years 2014, 2024 & 2030
GERMANY
- Metabolomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
- Table 74: Germany Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 75: Germany Historic Review for Metabolomics by Application - Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 76: Germany 16-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics and Other Applications for the Years 2014, 2024 & 2030
- Table 77: Germany Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 78: Germany Historic Review for Metabolomics by End-Use - Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 79: Germany 16-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End-Uses for the Years 2014, 2024 & 2030
ITALY
- Table 80: Italy Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 81: Italy Historic Review for Metabolomics by Application - Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 82: Italy 16-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics and Other Applications for the Years 2014, 2024 & 2030
- Table 83: Italy Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 84: Italy Historic Review for Metabolomics by End-Use - Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 85: Italy 16-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End-Uses for the Years 2014, 2024 & 2030
UNITED KINGDOM
- Metabolomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
- Table 86: UK Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 87: UK Historic Review for Metabolomics by Application - Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 88: UK 16-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics and Other Applications for the Years 2014, 2024 & 2030
- Table 89: UK Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 90: UK Historic Review for Metabolomics by End-Use - Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 91: UK 16-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End-Uses for the Years 2014, 2024 & 2030
REST OF EUROPE
- Table 92: Rest of Europe Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 93: Rest of Europe Historic Review for Metabolomics by Application - Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 94: Rest of Europe 16-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics and Other Applications for the Years 2014, 2024 & 2030
- Table 95: Rest of Europe Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 96: Rest of Europe Historic Review for Metabolomics by End-Use - Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 97: Rest of Europe 16-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End-Uses for the Years 2014, 2024 & 2030
ASIA-PACIFIC
- Metabolomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
- Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 99: Asia-Pacific Historic Review for Metabolomics by Application - Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 100: Asia-Pacific 16-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics and Other Applications for the Years 2014, 2024 & 2030
- Table 101: Asia-Pacific Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 102: Asia-Pacific Historic Review for Metabolomics by End-Use - Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 103: Asia-Pacific 16-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End-Uses for the Years 2014, 2024 & 2030
Companies Mentioned
- AB Sciex LLC
- African Biosciences Ltd
- Agilent Technologies, Inc.
- Agios Pharmaceuticals, Inc.
- Berg LLC
- BioCat GmbH
- Biocenter Finland
- Biocrates Life Sciences AG
- Biogenetics
- Bio-Rad Laboratories, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 268 |
| Published | December 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 3.5 Billion |
| Forecasted Market Value ( USD | $ 9 Billion |
| Compound Annual Growth Rate | 14.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
